CD38 is the Achilles heel of Multiple Myeloma because nearly every myeloma cell is covered in a massive amount of this protein. When we use a drug that targets CD38, it acts like a homing beacon for the patient’s own immune system. Once the drug attaches to CD38, it performs a triple-threat attack: it directly triggers the cell to self-destruct, it signals killer immune cells to eat the cancer, and it blocks the enzyme activity that the cancer uses to suppress the local immune environment. This makes it significantly more effective and precise than traditional chemotherapy, which attacks all fast-growing cells indiscriminately. Clinical results show that targeting CD38 can clear cancer cells even in patients who have failed multiple other types of treatment.

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease where the body’s immune system loses the ability to distinguish between "self" and "foreign" invaders. In Lupus, a specific group of long-lived plasma cells becomes hyperactive and produces auto-antibodies that attack the body’s own DNA and healthy tissues. These cells are often resistant to standard treatments because they hide deep within the bone marrow and tissues.The resulting inflammation can strike anywhere-the skin, joints, heart, and especially the kidneys (Lupus Nephritis). Over time, the constant production of these harmful antibodies leads to permanent organ scarring and cycles of debilitating "flares" where symptoms worsen significantly.